Back to results
US 11,898,209 B2Granted
Digital analysis of circulating tumor cells in blood samples
AssigneeThe General Hospital Corporation
InventorsDaniel A. Haber, Ravi Kapur, Mehmet Toner, Shyamala Maheswaran, Xin Hong, David Tomoaki Miyamoto, Tanya Todorova, Sarah Javaid
Life of this patent
Estimating the term…
Abstract
This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.
Claims19
A method for analyzing circulating tumor cells (CTCs) in a blood sample from a subject, the method comprising:
- isolating circulating tumor cells (CTCs) from the blood sample;
- isolating ribonucleic acid (RNA) from the CTC;
- generating cDNA molecules in solution from the isolated RNA;
- encapsulating cDNA molecules into individual droplets;
- amplifying cDNA within each of the individual droplets in the presence of one or more reporter groups configured to bind specifically to cDNA corresponding to tumor lineage-specific RNA from a specific type of tissue that is the source of the CTCs and not to bind to cDNA from normal cells in the blood;
- detecting droplets that contain the reporter groups as an indicator of the presence of amplified cDNA molecules from CTCs in the droplets;
- and
- analyzing cDNA molecules from CTCs in the detected droplet;
- wherein amplifying cDNA molecules within each of the individual droplets comprises conducting PCR in each droplet,
- wherein at least one primer set for each type of cancer is used for amplifying the cDNA molecules within each of the droplets, wherein each primer set corresponds to a selected cancer gene,
- wherein the selected cancer genes include prostate cancer-selective genes or breast cancer-selective genes,
- wherein the prostate cancer-selective genes are FAT1, TMPRSS2, AGR2, FOLH1, HOXDB13, KLK2, KLK3, and STEAP2,
- wherein the primer sets corresponding to the prostate cancer-selective genes are:
- FAT1 (primer 1 SEQ ID NO:23, primer 2 SEQ ID NO:22),
- TMPRSS2 (primer 1 SEQ ID NO:134, primer 2 SEQ ID NO:133),
- AGR2 (primer 1 SEQ ID NO:2, primer 2 SEQ ID NO:1),
- FOLH1 (primer 1 SEQ ID NO:29, primer 2 SEQ ID NO:28),
- HOXDB13 (primer 1 SEQ ID NO:32, primer 2 SEQ ID NO:31),
- KLK2 (primer 1 SEQ ID NO:35, primer 2 SEQ ID NO:34),
- KLK3 (primer 1 SEQ ID NO:38, primer 2 SEQ ID NO:37), and
- STEAP2 (primer 1 SEQ ID NO:125, primer 2 SEQ ID NO:124);
- and/or
- wherein the breast cancer-selective genes are TFAP2C, S100A2, PGR, PIP, FAT2, AGR2, FAT1, RND3, PKP3, PRAME, and SCGB2A1,
- wherein the primer sets corresponding to the breast cancer-selective genes are:
- TFAP2C (primer 1 SEQ ID NO:131, primer 2 SEQ ID NO:130),
- S100A2 (primer 1 SEQ ID NO:80, primer 79 SEQ ID NO:103),
- PGR (primer 1 SEQ ID NO:62, primer 2 SEQ ID NO:61),
- PIP (primer 1 SEQ ID NO:164, primer 2 SEQ ID NO:163),
- FAT2 (primer 1 SEQ ID NO:26, primer 2 SEQ ID NO:25),
- AGR2 (primer 1 SEQ ID NO:2, primer 2 SEQ ID NO:1),
- FAT1 (primer 1 SEQ ID NO:23, primer 2 SEQ ID NO:22),
- RND3 (primer 1 SEQ ID NO:77, primer 2 SEQ ID NO:76),
- PKP3 (primer 1 SEQ ID NO:65, primer 2 SEQ ID NO:64),
- PRAME (primer 1 SEQ ID NO:149, primer 2 SEQ ID NO:148), and
- SCGB2A1 (primer 1 SEQ ID NO:83, primer 2 SEQ ID NO:82).
32 more elements
Dependencies are inferred from the claim text.